ESPR earnings date and last-quarter result: last quarter miss, P/E -131.40. Updated 2026-07-23.
Esperion Therapeutics (ESPR) Research Hub
Esperion Therapeutics (ESPR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-07-14, shares last closed at 3.18 USD (-0.31%), in a uptrend — price above rising 50-DMA, 50-DMA above 200-DMA. Valuation: trailing P/E -131.40, market cap 0.66B. This hub links to the full technical, earnings and options research available for ESPR.
Last updated 2026-07-14 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.18 USD (-0.31%) |
| 52-week range | 1.13 USD – 4.18 USD |
| Trend regime | Uptrend |
| 14-day RSI | 58.3 (Bullish) |
| Trailing P/E | -131.40 |
| Market cap | 0.66B |
| Dividend yield | 99.37% |
Available research for ESPR
Covered Call on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ESPR: how it works, illustrative setup around the real 3.18 USD price, max profit/loss, breakeven and when to use it. Educational.
ESPR technical analysis: uptrend, last 3.18 USD, RSI 58.3, 52w range 1.13 USD–4.18 USD, real support/resistance. Updated 2026-07-14.
More on SniperIQ
Frequently asked questions
What sector is ESPR in?
Esperion Therapeutics (ESPR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ESPR in an uptrend or downtrend?
As of 2026-07-14, ESPR is in a uptrend — price above rising 50-DMA, 50-DMA above 200-DMA. See the full technical research page for support and resistance levels.
What is ESPR's trailing P/E ratio?
ESPR's trailing P/E is -131.40, with a market cap of 0.66B. See the earnings research page for full valuation detail.